-
1.发明申请METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS 审中-公开提高生物反应调节蛋白质效能的方法和示范性静息公开(公告)号：US20130089513A1
公开(公告)日：2013-04-11
申请号：US13437701
申请日：2012-04-02
申请人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
发明人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
IPC分类号： C07K14/52 , C07K14/535
CPC分类号： C07K14/52 , A61K38/00 , C07K14/524 , C07K14/535 , C07K14/715
摘要： Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种蛋白质变体，其通过结合受体，配体或底物，在具有生物反应调节功能的结合结构域中代替缬氨酸作为苯丙氨酸残基。 此外，本发明公开了编码蛋白质变体的DNA，可操作地连接DNA的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及制备蛋白质变体的方法，包括培养宿主细胞 并从所得培养物中分离蛋白质变体。 此外，本发明公开了包含蛋白质变体和药学上可接受的载体的药物组合物。
-
2.发明申请METHOD OF IMPROVING EFFICACY OF BIOLOGICAL RESPONSE-MODIFYING PROTEINS AND THE EXEMPLARY MUTEINS 审中-公开提高生物反应调节蛋白质效能的方法和示范性静息公开(公告)号：US20100041586A1
公开(公告)日：2010-02-18
申请号：US12499710
申请日：2009-07-08
申请人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
发明人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
IPC分类号： A61K38/16
CPC分类号： C07K14/52 , A61K38/00 , C07K14/524 , C07K14/535 , C07K14/715
摘要： Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种蛋白质变体，其通过结合受体，配体或底物，在具有生物反应调节功能的结合结构域中代替缬氨酸作为苯丙氨酸残基。 此外，本发明公开了编码蛋白质变体的DNA，可操作地连接DNA的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及制备蛋白质变体的方法，包括培养宿主细胞 并从所得培养物中分离蛋白质变体。 此外，本发明公开了包含蛋白质变体和药学上可接受的载体的药物组合物。
-
3.发明申请Method of improving efficacy of biological response-modifying proteins and the exemplary muteins 有权提高生物反应调节蛋白和示例性突变蛋白的功效的方法公开(公告)号：US20060008872A1
公开(公告)日：2006-01-12
申请号：US10519390
申请日：2004-09-30
申请人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
发明人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
CPC分类号： C07K14/52 , A61K38/00 , C07K14/524 , C07K14/535 , C07K14/715
摘要： Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种蛋白质变体，其通过结合受体，配体或底物，在具有生物反应调节功能的结合结构域中代替缬氨酸作为苯丙氨酸残基。 此外，本发明公开了编码蛋白质变体的DNA，可操作地连接DNA的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及制备蛋白质变体的方法，包括培养宿主细胞 并从所得培养物中分离蛋白质变体。 此外，本发明公开了包含蛋白质变体和药学上可接受的载体的药物组合物。
-
公开(公告)号：US07569361B2
公开(公告)日：2009-08-04
申请号：US10519390
申请日：2004-05-27
申请人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
发明人： Yong-Hoon Chung , Hak-sup Lee , Ki-Wan Yi , Youn-Hwa Heo , Jae-Youn Kim
IPC分类号： C07K14/00 , C07K14/475
CPC分类号： C07K14/52 , A61K38/00 , C07K14/524 , C07K14/535 , C07K14/715
摘要： Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing the protein variant comprising cultivating the host cell and isolating the protein variant from the resulting culture. Further, the present invention discloses a pharmaceutical composition comprising the protein variant and a pharmaceutically acceptable carrier.
摘要翻译： 公开了一种蛋白质变体，其通过结合受体，配体或底物，在具有生物反应调节功能的结合结构域中代替缬氨酸作为苯丙氨酸残基。 此外，本发明公开了编码蛋白质变体的DNA，可操作地连接DNA的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及制备蛋白质变体的方法，包括培养宿主细胞 并从所得培养物中分离蛋白质变体。 此外，本发明公开了包含蛋白质变体和药学上可接受的载体的药物组合物。
-
公开(公告)号：US20060247425A1
公开(公告)日：2006-11-02
申请号：US10555538
申请日：2005-05-31
申请人： Yong-Hoon Chung , Ki-Wan Yi , Hoon-Sik Cho , Hong-Gyu Park , Kwang-Seong Kim
发明人： Yong-Hoon Chung , Ki-Wan Yi , Hoon-Sik Cho , Hong-Gyu Park , Kwang-Seong Kim
CPC分类号： A61K38/1774 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/94 , C07K2319/30
摘要： The present invention relates to a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant, comprising one or more amino acid modifications selected from the group consisting of M160N, A195N, T243N, E265N, Y299T, F331T and Q346N, is additionally glycosylated, and a gene encoding the same. Also, the present invention relates to a glycosylated fusion protein formed as a result of linkage of (a) a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant having a modified amino acid sequence forming one or more Asn-X-Ser/Thr sequences is additionally glycosylated, with (b) at least one biologically active protein or a portion thereof, a gene encoding the same, a recombination expression vector comprising the gene, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing a glycosylated fusion protein comprising culturing the transformant or transfectant and isolating the glycosylated fusion protein from the culture, and a pharmaceutical composition comprising the glycosylated fusion protein thus prepared.
摘要翻译： 本发明涉及糖基化免疫球蛋白或其片段，其中包含一个或多个选自M160N，A195N，T243N，E265N，Y299T，F331T和Q346N的氨基酸修饰的免疫球蛋白变体另外被糖基化， 和编码该基因的基因。 此外，本发明涉及由（a）糖基化免疫球蛋白或其片段连接而形成的糖基化融合蛋白，其中具有形成一个或多个Asn-X-Ser / Thr序列另外被糖基化，（b）至少一种生物活性蛋白质或其部分，编码该基因的基因，包含该基因的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及方法 制备糖基化融合蛋白，包括培养转化体或转染子并从培养物中分离糖基化的融合蛋白，以及包含如此制备的糖基化融合蛋白的药物组合物。
-
公开(公告)号：US08871907B2
公开(公告)日：2014-10-28
申请号：US10555538
申请日：2005-05-31
申请人： Yong-Hoon Chung , Ki-Wan Yi , Hoon-Sik Cho , Hong-Gyu Park , Kwang-Seong Kim
发明人： Yong-Hoon Chung , Ki-Wan Yi , Hoon-Sik Cho , Hong-Gyu Park , Kwang-Seong Kim
CPC分类号： A61K38/1774 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/526 , C07K2317/94 , C07K2319/30
摘要： The present invention relates to a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant, comprising one or more amino acid modifications selected from the group consisting of M160N, A195N, T243N, E265N, Y299T, F331T and Q346N, is additionally glycosylated, and a gene encoding the same. Also, the present invention relates to a glycosylated fusion protein formed as a result of linkage of (a) a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant having a modified amino acid sequence forming one or more Asn-X-Ser/Thr sequences is additionally glycosylated, with (b) at least one biologically active protein or a portion thereof, a gene encoding the same, a recombination expression vector comprising the gene, a host cell transformed or transfected with the recombinant expression vector, and a method of preparing a glycosylated fusion protein comprising culturing the transformant or transfectant and isolating the glycosylated fusion protein from the culture, and a pharmaceutical composition comprising the glycosylated fusion protein thus prepared.
摘要翻译： 本发明涉及糖基化免疫球蛋白或其片段，其中包含一个或多个选自M160N，A195N，T243N，E265N，Y299T，F331T和Q346N的氨基酸修饰的免疫球蛋白变体另外被糖基化， 和编码该基因的基因。 此外，本发明涉及由（a）糖基化免疫球蛋白或其片段连接而形成的糖基化融合蛋白，其中具有形成一个或多个Asn-X-Ser / Thr序列另外被糖基化，（b）至少一种生物活性蛋白质或其部分，编码该基因的基因，包含该基因的重组表达载体，用重组表达载体转化或转染的宿主细胞，以及方法 制备糖基化融合蛋白，包括培养转化体或转染子并从培养物中分离糖基化的融合蛋白，以及包含如此制备的糖基化融合蛋白的药物组合物。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.026 秒)
